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SUMMARY
Background
Recent studies have shown that Gaviscon Double Action Liquid (a combi-
nation alginate-antacid) administered post-prandially co-localises with the
acid pocket, the ‘reservoir’ for post-prandial acid reﬂux.
Aim
To compare the effectiveness of Gaviscon Double Action Liquid to an
equivalent strength antacid without alginate in controlling post-prandial
acid reﬂux in GERD patients.
Methods
Fourteen GERD patients undertook two 3.5-h high-resolution manometry/
pH-impedance studies during which they ate a standardised meal. In a dou-
ble-blinded randomised crossover design they then took Gaviscon or CVS
brand antacid, each with ~18 mmol/L acid neutralising capacity. The primary
outcome was distal oesophageal acid exposure; secondary outcomes were
number of reﬂux events, proximal extent of reﬂux, nadir pH of the reﬂuxate,
mechanism of reﬂux and reﬂux symptoms scored with a validated instrument.
Results
Ten patients completed the study. Gaviscon studies had signiﬁcantly less distal
oesophageal acid exposure and greater nadir reﬂuxate pH in the 30–150 min
post-prandial period than antacid studies. There were no differences in the
number of reﬂux events (acid or weakly acidic) or the number of proximal
reﬂux events (15–17 cm above the LES) with either study medication.
Conclusions
Gaviscon Double Action Liquid is more effective than an antacid without
alginate in controlling post-prandial oesophageal acid exposure. However,
the number and spatial distribution of reﬂux events within the oesophagus
are similar. This suggests that Gaviscon main effectiveness relates to its co-
localisation with and displacement/neutralisation of the post-prandial acid
pocket, rather than preventing reﬂux.
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INTRODUCTION
Heartburn is a cardinal symptom of gastro-oesophageal
reﬂux disease (GERD) and is among the most common
patient complaints encountered by Internists and Gast-
roenterologists. A nationwide telephone survey of 21 000
representative US adults found that 6.3% of respondents
experienced heartburn on at least a twice-weekly basis.1 In
most instances, heartburn is experienced post-prandially. A
seeming paradox of post-prandial heartburn is that it
occurs during the period that one might expect gastric acid
to be buffered by the meal. That paradox was partially
resolved with the description of the ‘acid pocket’, the phe-
nomenon by which newly secreted gastric acid layers on
top of, rather than mixing with, the ingested meal.2, 3 This
puts acid in close proximity to the gastro-oesophageal junc-
tion as soon as 17 min after eating.4 Investigations using
either technetium labelled acid and scintigraphic monitor-
ing5 or high-resolution post-prandial pH recordings4 have
conﬁrmed that the acid pocket is the source of post-pran-
dial acid reﬂux. Furthermore, the acid pocket tends to
localise within a hiatal hernia, when present,5 and to facili-
tate the migration of acid across the squamocolumnar junc-
tion in patients with hernias or GERD.5, 6 Hence,
selectively targeting the acid pocket becomes an attractive
therapeutic approach for the management of post-prandial
heartburn.
Consistent with the central role of gastric acid in the
genesis of reﬂux symptoms and mucosal pathology, the
inhibition of gastric acid secretion has been the mainstay
of the medical management of GERD.7 Proton pump
inhibitors (PPIs) are particularly potent and have proven
to be extremely effective treatment for esophagitis. Not
surprisingly, PPIs have also been shown to both decrease
the size of and the acidity within the acid pocket.8, 9
However, PPI therapy has limitations. Many patients
have an incomplete symptom response and others, either
because of general unease with open-ended pharmaco-
therapy or because of the intermittent nature of reﬂux
symptoms, prefer to address reﬂux symptoms with prn
medication. The problem has been the limited efﬁcacy of
this approach; antacids neutralise gastric acid in a short
timeframe after ingestion but the effect is soon overcome
by meal-stimulated acid secretion. Alternatively, an algi-
nate-antacid combination creates a ‘raft’ ﬂoating on top
of the ingested chyme that co-localises in the region of
the acid pocket, potentially offering more effective tar-
geted therapy.10 This study compared the effect of Gavis-
con Double Action Liquid (Reckitt Benckiser Healthcare,
Hull, UK) to a store-brand antacid in controlling
post-prandial acid reﬂux in GERD patients.
METHODS
Study subjects
Typical GERD patients with past or present LA A or B
esophagitis and/or abnormal pH monitoring study (>5%
distal oesophageal acid exposure on Bravo pH monitor-
ing) along with a signiﬁcant frequency-severity of typical
gastro-oesophageal reﬂux symptoms gauged by the Ger-
dQ instrument (score ≥8) were recruited from a pool of
patients referred to the Northwestern Medical Faculty
Foundation (NMFF) Gastroenterology out-patient prac-
tice or the gastrointestinal diagnostic laboratory at
Northwestern Memorial Hospital from August 2011 to
March 2013. Those with prior gastrointestinal surgery,
or signiﬁcant cardiopulmonary, renal, neurological or
psychiatric disorders were excluded. Study participants
were asked to refrain from taking any proton pump
inhibitors or H2-receptor antagonists for 7 days prior to
their study sessions. Acid neutralising medications were
allowed as needed except for the day of the study. All
subjects gave written informed consent and the North-
western University Institutional Review Board (IRB)
approved the study protocol.
Study medications
Gaviscon Double Action Liquid (sodium alginate-bicar-
bonate) is an oral liquid suspension that belongs in the
pharmacotherapeutic group A02BX (other drugs for pep-
tic ulcer and gastro-oesophageal reﬂux disease). Its mode
of action is local, not depending on absorption into the
circulation. The medication is a combination of two antac-
ids (calcium carbonate and sodium bicarbonate) and
sodium alginate. Each 20 mL dose contains 1000 mg
sodium alginate, 426 mg sodium bicarbonate and 650 mg
calcium carbonate with an acid neutralising capacity of
approximately 18.1 mmol/L. Antacid Supreme (CVS
brand Antacid Liquid Supreme) is an oral liquid suspen-
sion that contains calcium carbonate 400 mg and magne-
sium hydroxide 135 mg in each 5 mL dose. Each 10 mL
dose has acid neutralising capacity of approximately
25.2 mmol/L. The volumes used were 20 mL of Gaviscon
Double Action Liquid and 7.5 mL of CVS antacid, each
with ~18 mmol/L acid neutralising capacity.
High-resolution manometry
High-resolution manometry data were obtained using a
solid-state assembly (4.2 mm outer diameter) with 36
circumferential sensors spaced at 1-cm intervals (Given
Imaging, Duluth, GA, USA), the recording characteristics
of which have been described previously.11 Studies were
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performed after at least a 6-h fast in a sitting position.
Pressure transducers were calibrated at 0 and 300 mmHg
using externally applied pressure prior to the study. Pres-
sure topography data were analysed using Manoview
analysis software (Given Imaging).
pH-impedance measurement
After manometric localisation of the lower oesophageal
sphincter (LES), an intraluminal pH-impedance catheter
[Sandhill Scientiﬁc, Highlands Ranch, CO, USA or Medi-
cal Measurement Systems (MMS), Enshede, the Nether-
lands] was positioned trans-nasally into the oesophagus
such that the oesophageal pH sensor was 5 cm above
the proximal margin of the LES. Intraluminal impedance
was continuously measured from six impedance-record-
ing segments; the middle of each impedance segment
was located at 3, 5, 7, 9, 15 and 17 cm above the proxi-
mal border of the OGJ as previously determined by
HRM. Impedance signals were recorded on a portable
digital data logger (Sandhill Scientiﬁc or MMS).
Study protocol
The protocol consisted of two 3.5-h study sessions, at
least 4 days apart. The GerdQ instrument was adminis-
tered to assess symptom severity for the 7 days prior to
each session during which time they were taking no
acid-suppressive medications. The HRM and pH-imped-
ance catheters were placed and recording begun. Partici-
pants then consumed a standardised meal consisting of a
McDonald’s double quarter pounder with cheese and
small fries (970 kcal) within about 15 min. Five minutes
after completion of the meal, one of the two medications
was administered by syringe into the subject’s mouth,
the identity of which was blinded to the patient. The
sequence of medication was allocated according to an
on-line computerised randomisation site (www.random-
izer.org). Post-prandial pH-impedance and HRM record-
ings continued for 180 min, during which the patients
were asked to complete a modiﬁed GerdQ each 30 min.
At the completion of the recording period, both catheters
were removed and the subjects were discharged.
Data analysis
The primary outcome of the study was the time that the
distal oesophageal pH was <4 in the 3-h post-prandial
period. Secondary outcomes were number of reﬂux
events, acid reﬂux events, proximal reﬂux events (15–
17 cm proximal to the LES), nadir pH of the reﬂuxate
and post-prandial symptoms experienced. Manometric
tracings were also analysed for the mechanism of reﬂux
associated with each reﬂux event. Criteria used to deﬁne
transient lower oesophageal sphincter relaxations (TLES-
Rs) were adapted from those proposed by Roman et al.
for pressure topography studies12 consistent with the
evolving recommendations of a multicenter expert panel
focused on this topic. All studies were reviewed by two
investigators (SR and AdR); discrepancies in interpreta-
tion were resolved by discussion inclusive of PJK. The
investigators were unaware of the medication given.
Statistical analysis
Data were expressed as median and interquartile range
(IQR) if nonparametric or mean  S.E.M. if parametric.
The Wilcoxon Rank Sum test and the Kruskal–Wallis
test were used to compare differences in nonparametric
metrics between groups. A paired t-test was used to
compare parametric results. All P-values were two-tailed
with the level of signiﬁcance deﬁned at 0.05. The study
was IRB approved to enrol a maximum of 20 subjects
based on the objective of detecting a 50% difference in
acid exposure time between study conditions and experi-
encing a high number of anticipated dropouts owing to
the rigours of the study.
RESULTS
Ten patients successfully completed both test sessions
with good quality recordings. Two subjects completed
only one session, declining to participate further, one
subject’s recording in one arm of the study was lost after
2 h of recording, and one subject’s recordings were cor-
rupted and unusable. Table 1 details the demographics
and entry characteristics of the completed patients.
All patients had typical GERD symptoms, evident by
all abnormal GerdQ scores prior to the ﬁrst study day.
Most of them (80%) were enrolled on the basis of having
had the recent demonstration of low-grade (LA A or B)
esophagitis on a recent endoscopy and the remaining
20% had pathological acid exposure on pH monitoring
performed while not taking a PPI.
Post-prandial oesophageal acid exposure
Evident in Table 2, the primary outcome of the study,
distal oesophageal acid exposure, was signiﬁcantly less
following Gaviscon compared to antacid.
Figure 1 illustrates the median, IQR, range and paired
oesophageal acid exposure data for each study partici-
pant, showing reasonable consistency in the effect among
study subjects. Figure 2 illustrates the mean nadir pH for
each 30-min post-prandial study period. Evident in the
ﬁgure, after the ﬁrst 30-min period the nadir pH was
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signiﬁcantly greater in the Gaviscon studies and this
effect persisted until 150 min post-prandially. Logically,
the decreased oesophageal acid exposure observed during
the Gaviscon studies was related to the decreased acidity
of the reﬂuxate during these periods.
Quantitative and qualitative characteristics of reﬂux
events
Despite the decreased acidity of reﬂuxate throughout
most of the post-prandial period, the number of acid
reﬂux events marginally failed to reach signiﬁcance over-
all (Table 2). In all likelihood, this was related to small
sample size. On the other hand, total reﬂux events (acid
and weakly acidic) were quite similar between study con-
ditions. Impedance data, also summarised in Table 2,
show similar numbers of reﬂux events during Gaviscon
and antacid studies. Similarly, there was no difference in
the number of proximal reﬂux events (15–17 cm
proximal to the LES). These observations were uniform
throughout all 30-min periods of the study protocol
suggesting no differences in either the propensity for
reﬂux or the distribution of reﬂux in the oesophagus
between study paradigms (Figure 3).
Mechanisms of reﬂux and reﬂux symptoms
When analysed by mechanism, most reﬂux events
occurred by transient LES relaxation (Table 3) with no
difference observed between study conditions.
Subjects reported relatively few reﬂux symptoms dur-
ing the studies, again with no systematic differences
between study conditions. It should, however, be noted
that subjects were somewhat uncomfortable during the
studies consequent of having two naso-oesophageal tubes
in place, perhaps masking reﬂux-related symptoms.
DISCUSSION
This investigation compared the effectiveness of Gavis-
con Double Action Liquid (alginate & antacid) to an
equally potent antacid without alginate in controlling
post-prandial acid reﬂux in GERD patients. Two 3-h
post-prandial impedance pH recordings combined with
HRM were done on each study participant in a dou-
ble-blind crossover design. The major ﬁndings of the
study were that Gaviscon was associated with signiﬁ-
cantly less distal oesophageal acid exposure than antacid
and that this was related to a greater pH of the reﬂuxate
rather than to a decrease in the number of reﬂux events
recorded in each study condition. The results suggest
that the primary mechanism of efﬁcacy for Gaviscon
Table 1 | Demographics and clinical features of ten
completed patients
Patient characteristic (n = 10) Value
Age in years (s.d.); gender 48 (11.6) 5 male
Weight in kg (s.d.) 90.4 (15.4)
Number enrolled based on history of L
A A esophagitis
4 (40%)
Number enrolled based on history of
LA B esophagitis
4 (40%)
Number enrolled based on abnormal
acid exposure on 48-h pH study
2 (20%)
Mean entry GerdQ score 9.5 (s.d. 1.2)
Table 2 | Post-prandial acid exposure and reﬂux data.
Gaviscon Double Action Liquid vs. antacid.
Gaviscon Antacid P
Distal acid
exposure:
median% (IQR)
0.7 (0–28.2) 8.0 (0–7.2) 0.001
Number of
acid reﬂux
events:
mean  S.E.M.
8.7  3.0 12.4  2.7 0.06
Total reﬂux
events:
mean  S.E.M.
22.5  4.9 25.1  7.3 0.54
Proximal reﬂux
events:
mean  S.E.M.
8.7  4.4 6.4  3.7 0.29
25
20
15
10
5
0
Gaviscon Antacid
Time (%)
pH<4
* P < 0.01
Figure 1 | Median, IQR, range (box plots) and paired
(dots) acid exposure times for study subjects during
Gaviscon Double Action Liquid (left, dashed line, white
dots) and antacid (right, black line, black dots) studies.
A consistent decrease was observed with Gaviscon
compared to the antacid with corresponding signiﬁcant
decrease in the median (P < 0.01).
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related to its demonstrated characteristic of localising
with and displacing (or neutralising) the post-prandial
acid pocket rather than serving as a mechanical barrier
to reﬂux.
Although the acid pocket was described long ago,13 its
relevance to reﬂux disease is only now coming to light.3
The initial observation was that the minimal pH of
oesophageal reﬂux was lower than the concomitant pH
recorded from within the stomach.2 Ultimately, this par-
adox was resolved with the description of the acid
pocket, the pool of newly secreted acid in the post-pran-
dial period that layers on top of ingested chyme rather
than mixing with it and serves as the reservoir for
post-prandial acid reﬂux events within as little as 17 min
of eating.4 Subsequent observations were that ingested
alginate co-localised with the acid pocket10 and could
displace or even neutralise it.14 The current investigation
adds to this with the demonstration that the effect of an
alginate–antacid combination was above and beyond that
of antacid after the ﬁrst 30 min and persisted for at least
2.5 h after the meal. These observations support the
persistence of the rafting effect of alginate also observed
with 3D MRI imagery.15
An alternative mechanism of action proposed for algi-
nates is of forming a barrier to reﬂux.15–17 The hypothe-
sis is that through molecular cross-linking, the
polysaccharides form a cap over the gastric content and
contains it within the stomach.16 If this were the operant
mechanism, one would anticipate a lesser number of
8
7
6
5
4
3
2
1
30 min 60 min 90 min 120 min 150 min 180 min
30 min time period
Nadir reflux
pH:
Mean ± SEM
per subject
Antacid
Gaviscon
* P < 0.01
* P < 0.05
* P < 0.01 * P < 0.05
P = 0.065
Figure 2 | Comparison of the
mean nadir pH of reﬂuxate
during each 30-min post-
prandial period during
Gaviscon Double Action Liquid
(white dots) and antacid
(black dots) studies. After the
ﬁrst 30 min, the nadir pH of
reﬂuxate was signiﬁcantly less
acidic during the Gaviscon
studies and this effect
persisted until 150 min
(P < 0.05, paired t-test).
8
7
6
5
4
3
2
1
30 min 60 min 90 min 120 min 150 min 180 min
30-min time period
Reflux
events:
Mean ± SEM
per subject
Antacid
Gaviscon
Distal ProximalFigure 3 | Comparison of the
number of reﬂux events (acid
and weakly acidic) observed
during the Gaviscon Double
Action Liquid (distal events
white dots and proximal
events white squares) and
antacid (distal events black
dots and proximal events
black square) studies. Similar
numbers total and proximal
events were observed
throughout the duration of the
recordings.
Table 3 | Mechanisms of reﬂux. No signiﬁcant
differences were seen between study paradigms. TLESR
was the dominant mechanism with both medications.
Data expressed as mean  S.E.M.
Reﬂux mechanism Gaviscon Antacid P
TLESR 10.9  2.0 11.5  1.2 0.6
Strain 8.8  4.9 10.8  7.8 0.3
Swallow 1.1  0.5 1.6  0.7 1.0
Hypotensive LES 1.7  1.4 1.0  0.6 0.6
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reﬂux events in the Gaviscon condition than in the
antacid condition. In this study, we observed only a
trend in acidic reﬂux events number decrease likely due
to the small sample size. One interesting ﬁnding of our
study was a shift in the content of the reﬂuxate to being
less acidic suggesting that by displacing the acid pocket,
it was now the alginate raft that was reﬂuxing rather
than gastric secretions. Comparing the Gaviscon to the
antacid studies, no differences were seen in either the
number of reﬂux events or in the number of reﬂux
events that reached the proximal oesophagus. Further-
more, there was no difference in the mechanism of
reﬂux, in each paradigm being dominated by transient
LES relaxation. Nonetheless, there was substantially less
oesophageal exposure on account of the increased pH of
the reﬂuxate during the Gaviscon studies.
Even though they had objectively less acid reﬂux, we
observed no difference in the symptoms experienced by
subjects during the Gaviscon studies. In fact, subjects
reported relatively few symptoms with either treatment.
This outcome is not surprising considering the complex
instrumentation and multiple naso-oesophageal intuba-
tions. The experimental setup does not lend itself to
detecting potentially subtle differences in reﬂux symp-
toms given the level of discomfort imposed by the exper-
imental setup itself. A better experimental design to
assess the impact of the medications on symptoms would
be a simple crossover comparison done without any
instrumentation with the outcome solely dependent on
scoring a questionnaire such as the GerdQ. Such a study
was recently conducted comparing Gaviscon Double
Action Liquid to placebo ﬁnding substantial decrease in
heartburn and regurgitation after Gaviscon administra-
tion.18
Limitations of this study include the immobility
imposed on the study subjects by the experimental setup
and, as already mentioned, the inherent discomfort of
the instrumentation that probably negated our ability to
analyse symptoms. Immobility potentially inﬂuences the
outcome in that it makes it signiﬁcantly less likely that
reﬂux would occur by any mechanism other than tran-
sient LES relaxation and it may be that the alginate effect
would be different with strain-induced or swal-
low-induced reﬂux.19 Testing that hypothesis would,
however, require an ambulatory manometry study,
equipment that we do not have at our disposal.
In conclusion, we conducted a physiological study to
compare the effectiveness of Gaviscon Double Action
Liquid, an alginate-antacid combination, to antacid in
controlling post-prandial acid reﬂux in a group of well-
deﬁned GERD patients. We found that Gaviscon
decreased post-prandial acid exposure in the distal
oesophagus and increased the nadir pH of the reﬂuxate.
The effect persisted for at least 2.5 h. Gaviscon did not,
however, decrease the number of reﬂux events or the prox-
imal extent of reﬂux within the oesophagus. These ﬁnd-
ings suggest that the dominant mechanism of action for
the alginate-antacid combination is to displace and or neu-
tralise the post-prandial acid pocket rather than mechani-
cally constraining it. Nonetheless, the observations suggest
a mechanism of action for the alginate-antacid combina-
tion uniquely suited to addressing post-prandial acid
reﬂux.
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